About Evalion
The company makes software for clinical trials that checks records against requirements and acts on important issues. Related tools test, monitor and analyze conversational voice agents. Customers can provide audio, transcripts and evaluation results.
Marcelo Camberos is chief executive officer and a director. Miguel Andres is an executive officer and director. The business uses a Miami address and identifies Wilmington, Delaware, as its legal-entity address. Evalion is made in San Francisco and Barcelona.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jun 4, 2025 | Jun 11, 2025amended Oct 15, 2026 | $1,115,000target not set | 21 | $53,095 | Simple Agreements for Future Equity (SAFEs)Rule 506(b) | Form D/A ↗1 earlier filing |
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Why Investors Backed Evalion
Evalion sells software for clinical trials. The product combines continuous record checks, connected data and controls for sensitive information. The likely investment case centers on applying optional AI tools to regulated work.
What the product does
The service spans websites, apps, APIs and customer accounts. Organizations can submit account details, usage logs, audio, transcripts and evaluation outputs. They can connect cloud storage or AI providers. Optional AI features can summarize content or run quality checks. Customers can limit or disable functions involving third-party AI providers.
Progress so far
Qualifying workloads can receive a Business Associate Addendum and added safeguards for protected health information. The service is HIPAA compliant and SOC 2 compliant. Evalion uses encryption in transit, access controls and monitoring among its security measures. It does not sell customer content or use that content to train general models for other customers.
We wrote this summary from public statements by Evalion and its investors. It is not investment advice.
Leadership Team
Executive officers and directors listed on Evalion's Form D filed Oct 15, 2026.